BCOP Updates 2023: Bundle
BCOP Updates modules are on-demand and allow you to review and complete at your convenience for up to one year following the release of the education.
Each module includes access to articles, pre-assessment questions, patient cases and the BCOP post-test. You may choose to complete all modules or select individual modules, receiving BCOP credit for each completed module which achieves a passing score of 75% or above.
The BCOP Updates bundle includes:
- BCMA-Directed Therapy in Relapsed/Refractory Multiple Myeloma: Clinical Trial Updates
- Updates in the Treatment of Relapsed/Refractory DLBCL
- Frontline Therapy in CLL: Role BTK Inhibitors
- Treatment Updates in mCRPC: PSMA-Directed Therapy
- A Changing Landscape in the Treatment of Metastatic Breast Cancer: Targeted Therapy for HER2-low Disease
- Colorectal Cancer: Targeting HER2 and BRAF
- Updates in Precision Oncology and the Role of Companion Diagnostics
- The Role of Immunotherapy in Head and Neck Cancer – Current Practice and Future Possibilities
- Asparaginase Aspirations: Updates in Asparaginase Products, Supportive Care and Therapeutic Drug Monitoring
- Treatment Updates in Uncommon EGFR Mutations
Get it now!
System Requirements
All online, interactive modules require a computer and a reliable internet connection.
If you have questions about these modules, please contact HOPA Education at education@hoparx.org.
Accreditation Statement
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by July 19, 2024.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of Board Certified Oncology Pharmacist (BCOP) credit. A BCOP statement of credit will be issued only upon completion of a post- activity evaluation form, and post-test, a passing grade of 75% or greater is achieved. BCOP credit must be claimed by July 19, 2024.
Disclosure of Conflicts of Interest
The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict
The Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.